All posts by imreal

Intentional Growth Drives Dental Care Alliance to Surpass 400 Allied Practices


“We could not be any prouder of our affiliations which are founded on a shared commitment to clinical excellence, exceptional patient experience, and thoughtful growth,” shared Dave Pegg, DCA’s Chief Growth Officer.

Dental Care Alliance (DCA) announces that it has surpassed 400 allied practices, the result of the leading DSO’s strategic efforts to affiliate with best-in-class doctors and teams that build market density to expand geographical reach and serve the lifetime needs of patients across all dental disciplines. With the number of new allied locations added, including entrance into the state of Tennessee, 2022 was one of DCA’s most successful years in its 30+ year history.

Founded in 1991, by Dr. Steve Matzkin with two dental practices in Sarasota, Florida, DCA now consists of over 400 allied practices across six divisions. In 2022, DCA announced the formation a dedicated Adult Specialty Division, to complement its General Dentistry and Orthodontics & Pedodontics Divisions, reflecting the evolution of business, intentional growth, and resulting need for dedicated leadership and support by practice type. DCA’s portfolio of dedicated allied specialty practices has grown to include over 50 standalone specialty and over 70 standalone orthodontic and pediatric locations, reflective of DCA’s strength in supporting specialty focused dentistry.

Over the last 32 years, DCA has consistently evolved and thrived in all market conditions, resulting in its supported practices continuing to outpace industry performance, through focus on patients, their health, and its allies’ ability to provide safe, accessible, high-quality dental services.

“Achieving this impressive milestone demonstrates that, as an organization, DCA is focused on growing intentionally and partnering with practices that believe in the same things that we do,” commented Jerry Rhodes, Chief Executive Officer. “Our foundation and everything we do is centered on making our allied practices and dental health care teams much better with DCA than they would be otherwise. I could not be prouder of this organization and our devoted team members, as we continue to grow stronger together.”

In the first half of 2023, DCA continues to focus on supporting allies, unlocking growth, and strengthening its position as one of the largest and most diverse Dental Support Organizations in the country, poising the organization for another year of unprecedented growth.

“2022 was another unprecedented year for DCA affiliations, which we wholeheartedly believe was the result of focused efforts to affiliate with best-in-class doctors and teams,” shared Dave Pegg, DCA’s Chief Growth Officer. “We could not be any prouder of our affiliations which are founded on a shared commitment to clinical excellence, exceptional patient experience, and thoughtful growth. That shared philosophy drives each new affiliation and brings to life our mission, vision, and values. As we celebrate this wonderful milestone, we want to express our sincere respect and gratitude to all of our affiliations in making DCA their partner of choice.”

Dental Care Alliance’s mission is to advance the practice of dentistry by partnering with and supporting dental professionals to create a lifetime of healthy smiles. DCA currently supports over 400 allied practices and more than 900 dentists across 22 states. DCA’s allied practices represent all dental specialties and treat patients under more than 150 brand names.

Share article on social media or email:

New Supplement Now Available to Public from Options Medical Weight Loss


Sugar Blocker supplement by Options Medical Weight Loss.

Do you know what too much sugar in the blood does? It turns into fat. Sugar blocker is going to stop that process from happening.

The team at Options Medical Weight Loss is excited to release Sugar Blocker to the public! As part of Options’ vast offerings, the team at Options developed Sugar Blocker, a supplement that aids in controlling blood glucose throughout the day and works to block sugar absorption in the digestive system.

Sugar Blocker works to increase the body’s utilization of sugars and helps to maintain stable blood glucose, decreasing insulin spikes. With blood sugar levels stable, you will experience less food cravings, sustainable energy, and weight loss when paired with a healthy diet and exercise.

Benefits:

  • Stabilizes blood sugar
  • Degreases food cravings
  • Increases energy
  • Promotes weight loss
  • May increase muscle mass

Hear from Options Medical Weight Loss Chief Medical Officer, Dr. Katrina Mattingly how Sugar Blocker works.

How it’s used

Sugar Blocker is a supplement that can be taken before a meal or as needed to stabilize blood sugar levels. It does not contain stimulants and is a safe solution for people with diabetes, pre-diabetes, or those looking to control blood sugar levels. Before use, talk to a medical provider if you have been diagnosed with Diabetes Mellitus, or take insulin or oral hypoglycemics.

How to Get Started

Individuals interested in Sugar Blocker can purchase now, but we do recommend meeting with an Options weight loss specialist for free metabolic testing and a complimentary consultation. With the support of board-certified obesity doctors, together, you will receive a custom-tailored weight loss program that is aimed at achieving your specific goals. Options provides a variety of scientifically proven solutions and offers different weight loss services, including physician supervised programs, prescription weight loss medications, lipotropic injections, meal replacements, and one-on-one weight loss counseling.

Patients can start their journey by signing up for a free consultation on our website or by calling 888-405-LOSE (5673).

About Options Medical Weight Loss:

Options Medical Weight Loss was founded in 2014 in Chicago, Illinois and has since opened locations throughout Illinois, Ohio, Florida, and Arizona, with continued plans to expand to more states. Options Medical Weight Loss has helped more than 25,000 patients achieve their weight loss goals.

Hear from Options Medical Weight Loss Chief Medical Officer, Dr. Katrina Mattingly – what makes Options Medical Weight Loss different.

Share article on social media or email:

Everest Group Declares ‘The Age of Decentralized Clinical Trials Has Begun’


Everest Group

Everest Group

Today, pharmaceutical companies are optimistic about and investing in DCT trials, and Everest Group sees great potential in the market; however, because the technology and adoption is nascent, additional stakeholder education, product innovation and partnerships are needed.

Everest Group today released its latest research report on Decentralized Clinical Trials, which documents a 38% increase from 2021 to 2022 in the number of trials conducted with a decentralized and/or virtual component. Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront.

DCTs enable patients to participate in a clinical trial from the comfort of their homes through the use of technology (such as sensors or remote monitoring devices) and home-visit services. In an Everest Group survey of buyers of DCTs, interviewees reported that 20-25% of their trial portfolios were decentralized or hybrid in nature today, but that 80-90% of their trial portfolios will be decentralized/hybrid by 2027. When asked to name the biggest benefit of DCTs, two out of three of those buyers interviewed (67%) cited “improved patient enrollment and retention rates.” Other benefits named include reduced cost (20%), reduced trial timelines (13%), more diverse patient populations (13%), getting real time data (7%), and enabling complex scoring and analysis (7%).

These findings and more are detailed in the Decentralized Clinical Trials Adoption Playbook. This playbook looks at more than 50 DCT case studies across different therapy areas and informs enterprises about the trends, benefits and challenges in DCT adoption to help them design a strategy for seamless DCT adoption. (A complimentary abstract of this report is available for download.)

Everest Group also released today its 2023 Life Sciences Decentralized Clinical Trial Platforms State of the Market Report, which analyzes the current state of the DCT market. The report explores adoption and market trends; the DCT platform providers’ landscape; the enterprise view of DCT platform providers; Environment, Social, and Governance (ESG) initiatives; and emerging technology opportunities in the industry. (A complimentary abstract of this report is available for download.)

Pandemic Spotlight on DCTs Revealed Major Benefits to the Approach

Traditional clinical trials are an expensive affair, costing upwards of US$2.6 billion and up to 12 years in research effort before approval by a regulatory body. Additional burdens of the traditional approach are patient recruitment challenges, patient adherence and engagement challenges, and regulatory challenges.

During the COVID-19 lockdowns, clinical trial activity came to a halt because patients could no longer travel to hospital networks to participate in a clinical trial. Fortunately, DCTs breathed new life into these paused clinical trials and delivered a host of benefits beyond those offered by the traditional clinical research approach. As a result, enterprises have accelerated their plans toward DCT adoption, looking to convert their piecemeal deployments into a comprehensive strategy aimed at enhancing the trial experience for patients, sponsors and Contract Research Organizations. Additionally, recent technological advances, the proliferation of wearables, and the regulatory pressure on the industry to adopt DCTs following the pandemic have made the DCT landscape ripe for disruption.

Everest Group Partners with DTRA

Everest Group also announced today that it has joined the Decentralized Trials Research Alliance (DTRA) to support the organization’s mission of advancing policies, research practices and new technologies to make clinical trial participation widely accessible.

“Today, pharmaceutical companies are optimistic about and investing in DCT trials, and Everest Group sees great potential in the market; however, because the technology and adoption is nascent, additional stakeholder education, product innovation and partnerships are needed,” said Nitish Mittal, partner at Everest Group. “DTRA is one of the few bodies which is driving standardization in the process and stakeholder education in this space. We’re pleased to support the DTRA mission and to contribute by giving DTRA members access to Everest Group’s curated clinical development technology research.”

A frontrunner in the research of clinical technology, Everest Group has a deep research portfolio focused on the demand and supply side of DCTs. By partnering with DTRA, Everest Group aims to disseminate information about the DCT market (such as DCT product suppliers and their capabilities, enterprise DCT adoption trends and sourcing considerations, DCT state of the market, etc.) to various stakeholders responsible for adoption and continued success of DCTs.

About Everest Group

Everest Group is a leading research firm helping business leaders make confident decisions. We guide clients through today’s market challenges and strengthen their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. Our deep expertise and tenacious research focused on technology, business processes, and engineering through the lenses of talent, sustainability, and sourcing delivers precise and action-oriented guidance. Find further details and in-depth content at http://www.everestgrp.com.

Share article on social media or email:

Aging Media Network Announces 2023 Aspect Awards Winners


News Image

Aging Media Network (AMN) is proud to announce the winners of the 2023 Aspect Awards. With 53 submissions in the categories of Home Health & Home Care, Hospice & Palliative Care, Senior Housing & Senior Living, Skilled Nursing (SNF), and Behavioral Health, the scope of creativity is broader than ever before.

The program was judged by 10 individuals from across the care continuum, with expertise in sales, marketing and public relations. Entries were evaluated based on creativity, style and impact, quality, and goals and results. Each industry/category received first, second and third place decisions, classified by entries submitted among either vendors or providers.

“Creating great advertising and marketing campaigns to raise both awareness and differentiation will be critical for the entire healthcare industry to grow,” said George Yedinak, Executive Vice President of Aging Media Network. “This year’s Aspect Awards entries showcase the strategic and creative driving forces behind this movement.”

Participation from national, regional and local companies, as well as an array of creative agencies, makes the Aspect Awards a powerful benchmark for longevity marketing and creative strategy in 2023.

Introducing the 2023 Winners in alphabetical order, sorted by industry and category:

BEHAVIORAL HEALTH

Multimedia Campaign

Provider

Winner: Avera Health

Rebranding

Vendor

Winner: Dreamscape Marketing    

HOME HEALTH & HOME CARE

Audio / Radio / Podcast Campaign

Provider

Winner: Healing Hands Healthcare

Digital Display / PPC Campaign

Provider

Winner: Help at Home

Vendor

Winner: GA Creative on behalf of Providence

Multimedia Campaign

Provider

Winner: Sonas Home Healthcare & The Symphony Agency

Second Place: Avera Health

Third Place: Innovive Health

Print / Direct Mail / Billboard Campaign

Provider

Winner: Faith Home Healthcare

Rebranding

Provider

Winner: VNS Health

Second Place: FirstLight Home Care

Vendor

Winner: WellSky

Second Place: CHAP Inc

Social Media Campaign

Vendor

Winner: Forcura

Video / TV Campaign

Vendor

Winner: CHAP Inc

Second Place: CHAP Inc

HOSPICE & PALLIATIVE CARE

Multimedia Campaign

Provider

Winner: VITAS Healthcare

Second Place: St. Croix Hospice

New Brand Launch

Provider

Winner: Centrica Care Navigators

Second Place: Goldencare Hospice and Palliative Care LLC

Print, Direct Mail & Billboard Campaign

Vendor

Winner: Partner Plus Media/HPH Hospice, a Chapters Health Affiliate

Rebranding

Vendor

Winner: Maxwell Healthcare Associates

Video / TV Campaign

Provider

Winner: VITAS Healthcare

SENIOR HOUSING & SENIOR LIVING

Audio / Radio / Podcast Campaign

Provider

Winner: Priority Life Care / Her Stories

Second Place: Arrow Senior Living Management

Multimedia Campaign

Provider

Winner: Ohio Living

Second Place: Optima Living

Third Place: Optima Living

Vendor

Winner: Spark + Buzz Communications – Wilshire Finance Company

New Brand Launch

Provider

Winner: Arrow Senior Living Management

Second Place: Monark Grove / Beztak

Third Place: The Claiborne

Vendor

Winner: The Senior Team, Inc

Print, Direct Mail & Billboard Campaign

Provider

Winner: Christian Living Communities

Second Place: Friendship Village

Rebranding

Provider

Winner: Covenant Living Communities and Services

Second Place: Arrow Senior Living Management

Social Media Campaign

Provider

Winner: Arrow Senior Living Management

Video / TV Campaign

Provider

Winner: Arrow Senior Living Management

Second Place: Optima Living

Third Place: Holbrook Life

SKILLED NURSING (SNF)

Rebranding

Provider

Winner: Powerback Rehabilitation

Social Media Campaign

Provider

Winner: EmpowerMe Wellness

Second Place: Majestic Care

Vendor

Winner: GA Creative on behalf of Providence

Video / TV Campaign

Provider

Winner: Accolade Healthcare

About Aging Media Network

Aging Media Network is an innovative publishing company based in Chicago, Illinois, and is the publisher of Senior Housing News, Home Health Care News, Hospice News, Skilled Nursing News, and Behavioral Health Business.

Share article on social media or email:

CMI Media Group Appointed by Two Top US Pharmaceutical Companies as Omnichannel DTC & HCP Media Planning and Buying AOR


“The pitches we’ve been involved in are with highly competitive, exciting clients. What put us in the winner’s seat is our ability to work in very precise marketing,” said Joe Warren, EVP, Growth.

CMI Media Group, a leading global healthcare media strategy, planning, innovation and buying agency and part of WPP (NYSE: WPP), announced it has been chosen by two top global pharmaceutical companies as Agency of Record, with a focus on providing audience-led, insights-driven DTC and HCP media, omni-channel and analytics services. In both assignments, CMI Media Group will handle the companies’ US DTC and HCP omnichannel media planning and buying. The agency is tasked with developing media plans targeting both doctors and patients/consumers.

CMI Media Group delivers high ROI media performance and precision solutions to clients, fueled by talent, data, technology and amplification of creative. The company’s data-focused capabilities and omnichannel approach in action – dubbed “omnidynamic” by the CMI Media Group – have led to significant growth and success. In 2021 and 2022, the organization was recognized by Adweek as one of the fastest-growing agencies in the world.

“The pitches we’ve been involved in are with highly competitive, exciting clients. What put us in the winner’s seat is our ability to work in very precise marketing,” said Joe Warren, EVP, Growth. “In healthcare, today it’s more important than ever to engage healthcare professionals and patients with the information they need where and when they want it, and we are able to deliver on those capabilities for our clients. We are breaking paradigms in how data is used.”

Two of the company’s cutting edge and proprietary technologies helped propel them to both wins. Empower ™, the company’s integrated planning platform, is the health industry’s first and only end-to-end planning platform that enables continuous and personalized “insight to action” at scale. Empower allows CMI Media Group to close the loop on integrated DTC/HCP audience planning, messaging and outreach, making every campaign more effective. The platform offers cross-audience customer universe identification, segmentation, media planning, activation, measurement and on-going people-based optimization.

In addition to Empower, CMI Media Group’s PROACT™, which stands for Personalized & Responsive Omni-Channel Automated Customer Targeted, is the first and industry-leading healthcare media orchestration and automation platform, to get from data to insights to actions immediately. PROACT is the clear market leader with more active partners than any other platform and the flexibility and history to support every omnidynamic use case.

The successes are part of a winning streak that has led the company to remarkable YOY growth.

CMI Media Group is WPP’s leading healthcare media specialist. The company has brought many firsts to healthcare marketing as the leading healthcare-focused media buying and planning resource to the world’s game changers in pharma and life sciences.

Those looking to join the CMI Media Group team can visit the company’s career page for more information and a link to apply: https://cmimediagroup.com/careers/

About CMI Media Group

CMI Media Group, a WPP company (NYSE: WPP, http://www.wpp.com), is a full-service global media agency focused solely on health, wellness, and pharmaceutical marketing. CMI Media Group’s core offerings include Audience Strategy, Planning, Development, and Insights; Data and Analytics; Buying and Investment; and Direct Response and Customer Experience. As the leading media resource for the world’s top healthcare companies, CMI Media Group brings together leading technology, data, and talent to deliver seamless capabilities for clients. CMI Media Group has been recognized as a leader in DE&I, talent retention and employee development as well as one of the industry’s best places to work. To apply for a position within our teams visit https://cmimediagroup.com/careers/

Share article on social media or email:

myFace is a Platinum Supporter of the 80th Annual Meeting of the American Cleft Palate Craniofacial Association (ACPA)


myFace staff at ACPA’s 2022 Annual Meeting, from left to right: Dina Zuckerberg (Director of Family Programs), Stephanie Paul (Executive Director), and Sandy Gilbert (Senior Program Director).

“ACPA’s collaboration with myFace over the past several years has proven to benefit patients and providers, which is the ultimate goal of both organizations,” said ACPA Executive Director Adam Levy, CAE.

myFace is pleased to announce that the organization will be a Platinum Supporter for The American Cleft Palate Craniofacial Association’s (ACPA) 80th Annual Meeting, taking place May 2-6 in Raleigh, NC.

ACPA is a nonprofit association of individuals and healthcare professionals who are interested in clinical care and research advancements for those affected by cleft and craniofacial conditions. The meeting will feature sessions on advances in research and clinical and team-driven care; including poster sessions, panel presentations, and study sessions.

myFace is a national nonprofit dedicated to changing the faces – and transforming the lives – of children and adults with facial differences by providing them with access to holistic comprehensive care, education, resources and support that pave the way for better outcomes. myFace accomplishes this through:

(1) Providing grants to craniofacial centers across the country that allow them to deliver medical, dental/orthodontic, and psychosocial care, regardless of patients’ ability to pay;

(2) Direct services that meet the day-to-day needs of the craniofacial community, including Virtual Support Groups for parents, prenatal parents, adults, and adolescents; complimentary stays in the myFace Family Apartments when a patient needs to receive treatment in NYC, and free Newborn Craniofacial Care Kits given to families in need by our 37 hospital partners; and

(3) Public awareness and education efforts including our Transforming Lives Webinar Series, our myFace, myStory: Voices from the Craniofacial Community monthly podcast, and our myFace Wonder Project school assemblies, which strive to raise public awareness about craniofacial differences and foster inclusion.

myFace and ACPA entered into a partnership in 2022 to best leverage the strengths of each organization in providing resources and support for families impacted by a craniofacial conditions. myFace’s support of ACPA’s Annual Meeting underscores its deep commitment to this partnership – and to the wider craniofacial community.

“myFace is delighted to be a major supporter of ACPA’s Annual Meeting – which provides tremendous value to the craniofacial community by bringing together healthcare providers from around the world to share their findings in order to elevate craniofacial care,” said myFace Executive Director, Stephanie Paul. “This is yet another way in which myFace seeks to partner with the ACPA to provide resources that will help to transform the lives of those impacted by a craniofacial difference.”

myFace has recently partnered with ACPA in several other ways as well. In early 2022, myFace provided an educational grant to ACPA to publish a stand-alone issue of ACPA’s peer-reviewed Cleft Palate Craniofacial Journal to focus attention on the psychosocial needs of our community. myFace has also been partnering with ACPA to expand the reach and impact of its signature Transforming Lives webinar series. myFace and ACPA have also begun to partner on advocacy initiatives that serve our community, such as the Ensuring Lasting Smiles Act (ELSA). This bill would close loopholes that allow insurance companies to deny medically and dentally necessary treatment and services for patients with congenital conditions by ensuring that any procedure that restores function caused by a congenital condition would be covered by insurance.

“ACPA’s collaboration with myFace over the past several years has proven to benefit patients and providers, which is the ultimate goal of both organizations,” said ACPA Executive Director Adam Levy, CAE. “In serving intersecting communities, we’re grateful not only for myFace’s support of the 2023 Annual Meeting, but for our continued partnership in delivering services and resources to patients and their families.”

ABOUT MYFACE

Almost every hour a child in the US is born with a craniofacial difference. Each year, the faces of another 100,000 individuals are disfigured through accident or disease. These individuals join a community of hundreds of thousands who will navigate a unique journey of care and support throughout their lives. myFace is there to ensure that individuals and families in the craniofacial community receive the care, tools, and information they need to successfully navigate that journey.

For more than 72 years, myFace has provided access to care to the thousands in need each year by providing grants to top-level medical institutions. We also offer direct services through support groups, newborn craniofacial care kits, and housing for families during medical visits. myFace educates the broader community through free topic-specific webinars, workshops, and online resources. We raise critical public awareness about craniofacial differences through student assemblies that promote kindness and inclusion, and through our podcast series, where individuals can share their stories, be seen and be heard. For more information, please visit myface.org.

ABOUT ACPA

The American Cleft Palate Craniofacial Association (ACPA) is an interdisciplinary nonprofit 501(c)(3) association of interested individuals and healthcare professionals who treat and/or perform research on oral cleft and craniofacial conditions. ACPA members provide quality care for their patients. Since 1943, ACPA has worked to optimize outcomes for individuals with oral cleft and craniofacial conditions through education, support, research, advocacy, and interdisciplinary team care. ACPA members represent more than 30 disciplines in more than 50 countries worldwide. ACPA also provides information to affected individuals and families and seeks to educate the public about facial differences through its ACPA Family Services program. For more information, please visit acpacares.org.

Share article on social media or email:

Synterex Granted Micro-, Small and Medium-Sized Enterprise (SME) Status by the European Medicines Agency’s SME Office


“Having SME status will allow us to partner with both new and existing customers looking to expand into the region leveraging our regulatory services, which will help us accomplish our goal of getting new medicines to as many patients as possible.”

Clinical and regulatory consulting firm Synterex, B.V., a wholly owned subsidiary of Synterex, Inc., has been granted Micro-, Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency’s (EMA) SME office.

This newly granted SME status would allow Synterex access to early and frequent regulatory interactions during drug development for human and veterinary medicines. Additionally, Synterex would be eligible for other incentives such as multi-language translation of regulatory documentation required for market authorization and potential fee reductions or waivers.

“The support that the EMA provides for SMEs will greatly benefit Synterex as we continue to expand our operations across Europe,” said Synterex President Jeanette Towles. “Having SME status will allow us to partner with both new and existing customers looking to expand into the region leveraging our regulatory services, which will help us accomplish our goal of getting new medicines to as many patients as possible.”

The EMA plays a central role in facilitating the development and authorization of medicines across Europe. The SME initiative promotes innovation from smaller companies to ensure Europe continues to be a favorable environment for preclinical and clinical development of promising new therapeutic options. Detailed information on SME status can be found here.

For more information on Synterex, please visit http://www.synterex.com or join the conversation by liking and following us on the company’s social media channels: Twitter and LinkedIn.

About Synterex, Inc.:

Synterex is a WBENC-Certified Women’s Business Enterprise and disability-owned global clinical and regulatory consulting firm that provides clinical development solutions.

Delivering quality regulatory documentation requires navigating an evolving landscape influenced by regulators, research committees, healthcare professionals, and—most importantly—the scientific method itself.

At Synterex, we forge lasting and meaningful relationships that flex with the dynamic nature of science and technology.

Our staffers are seasoned and dedicated, with extensive experience doing the work hands-on as well as building and leading teams. We are committed to applying our years of experience and current subject matter and technical knowledge to help clients deliver important new therapies to patients in an expedient manner.

Share article on social media or email:



Salimetrics Launches + Stress Add-on for At-Home Sleep Testing


Sleep and Stress Test

When cortisol levels are elevated due to stress or other factors, it can interfere with the production and regulation of melatonin, the hormone responsible for promoting sleep.

Few objective measures exist on a physiological level that can be routinely implemented to reveal the exact timing of different circadian phases. However, individuals now have the flexibility to perform a home-based Sleep + Stress Assessment by including salivary cortisol, a well-known stress hormone. The + Stress add-on is available for all three (3) Circadian Phase Assessments: Dim Light Melatonin Onset (DLMO), Dim Light Melatonin Offset (DLMOff), and the 24-Hour Circadian Phase Map, providing a clearer window into each individual’s unique circadian physiology. “By measuring both cortisol and melatonin at the same time, it is possible to gain more insight into the body’s internal 24-hour “clock” that regulates many physiological processes, including sleep and wakefulness, hormone production, and metabolism,” says Steve Granger, Ph.D., Chief Scientific Officer at Salimetrics.

Measuring melatonin and cortisol levels simultaneously over multiple time points can help check for disruptions to the normal circadian rhythm, which may be indicative of certain sleep disorders, depression, or chronic stress. “While the production of melatonin is controlled by the body’s internal clock in response to light and darkness, and is highest at night to promote sleep, cortisol is released by the adrenal gland in response to stress and is typically highest in the morning and decreases throughout the day,” says Granger. “When cortisol levels are elevated due to stress or other factors, it can interfere with the production and regulation of melatonin, the hormone responsible for promoting sleep. In effect, elevated cortisol around bedtime means your body is physiologically heading in the opposite direction when you are trying to fall asleep, stay asleep, or obtain restorative sleep. Additionally, cortisol levels that are too low can also impact sleep quality. Therefore, maintaining normal cortisol levels is also important for overall sleep health.”

While melatonin testing was central to the initial circadian phase assessment, Salimetrics worked quickly to add the stress component as an optional add-on. “While we recognize the importance of the cortisol/melatonin relationship, our initial launch goal was to keep pricing as low as possible,” says Granger. “However, the potential of this relationship is often invaluable in treating sleep-related disruptions, so we worked quickly to make it available as part of our online test menu.”

Now, sleep medicine providers have a community-driven tool to aid in the management of circadian rhythm sleep-wake disorders (CRSWD) which can be utilized in two ways – firstly, to establish a baseline understanding of an individual’s physiological rhythms, and secondly, to focus on specific targets for treatment. By adopting a community-driven approach, Salimetrics is building a more comprehensive system that is better equipped to meet the diverse needs of its providers. “We’ve been committed to incorporating feedback from both the sleep medicine community and the patients themselves to continually enhance the ease and effectiveness of our sleep tests since inception,” says Granger.

Sleep health providers can visit https://biologyofsleep.com to learn more about how to integrate circadian phase assessments or to register in 5 minutes or less. Once registered, providers can immediately refer patients to order their assessment kit. From there, Salimetrics facilitates the in-between steps, until results are sent to the provider and patient through a HIPAA compliant results portal.

About Salimetrics

Salimetrics’ assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health, and immune function. Founded in 1998 by Douglas A. Granger, Ph.D., Salimetrics, LLC supports CROs, pharmaceuticals, academic researchers, and the immunodiagnostic industry worldwide with innovative immunoassay products, non-invasive saliva collection methods, and laboratory testing services.

Share article on social media or email:

Prevent Blindness Designates April as Women’s Eye Health and Safety Month to Educate Public on a Variety of Women’s Vision Issues


Prevent Blindness declares April as Women’s Eye Health and Safety Month to encourage women to make their vision a priority.

“We encourage women to be a model for good health by making their eyecare a priority today to ensure healthy vision for years to come,” said Kira Baldonado, Vice President of Public Health and Policy at Prevent Blindness.

Two out of every three people living with blindness or vision problems are women, according to the National Eye Institute. That’s why Prevent Blindness, the nation’s leading nonprofit eye health organization, has declared April as Women’s Eye Health and Safety Month. Because many of the effects of vision loss from eye disease can be lessened if detected and treated early, the group offers a variety of expert-reviewed free resources, including videos, fact sheets and shareable social media graphics on a range of eye health issues. Information on eye safety topics, including contact lenses, cosmetics and ultraviolet (UV) protection is also available.

For some, pregnancy brings an increase in hormones that may cause changes in vision. In most cases, these are temporary eye conditions that will return to normal after delivery. Those with pre-existing eye conditions, such as diabetes, high blood pressure, and glaucoma, should inform their eye doctor of their pregnancy to help monitor their health.

Women who are perimenopausal (nearing menopause) or already in menopause may also experience vision changes. Dry eye occurs at double the rate in postmenopausal women, according to the American Academy of Ophthalmology (AAO).

Women have a higher prevalence of many of the major vision problems, including:

  • Age-related Macular Degeneration
  • Cataract
  • Dry Eye
  • Glaucoma
  • Refractive Error
  • Thyroid Eye Disease

The AAO also states that women are more susceptible to autoimmune diseases than men, many of which affect vision, such as lupus and Sjögren’s syndrome.

As part of the Prevent Blindness Focus on Eye Health Expert Series, Janine Austin Clayton, M.D., FARVO, Associate Director for Research on Women’s Health and Director, Office of Research on Women’s Health at the National Institutes of Health (NIH), shares her thoughts on a variety of women’s eye health issues including equitable access to eyecare, addressing the impact of vision loss on mental health, and more in the new “Women’s Eye Health and Safety” episode.

In regards to eye safety, according to the Centers for Disease Control and Prevention (CDC), two-thirds of the 45 million people in the United States who wear contact lenses are women. Prevent Blindness reminds everyone that a prescription from a qualified eyecare professional is required to legally purchase contact lenses in this country, and to always wear contact lenses under the supervision of an eye doctor. Tips for safely caring for contact lenses may be found at: preventblindness.org/wearing-contact-lenses/

“Women lead incredibly busy and diverse lives- from running companies to running households. It is critical for women to take care of their own health needs, including eye health, to ensure they can be there for others,” said Kira Baldonado, Vice President of Public Health and Policy at Prevent Blindness. “We encourage women to be a model for good health by making their eyecare a priority today to ensure healthy vision for years to come.”

For more information on women’s eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org. Prevent Blindness also offers a free listing of financial assistance services in English and Spanish at: preventblindness.org/vision-care-financial-assistance-information/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Share article on social media or email:

Using Proteomics to Build Next-Gen Diagnostic Solutions, Upcoming Webinar Hosted by Xtalks


Directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.

Personalized oncology aims to match each patient to a specific therapy based on the molecular characteristics of their tumor. Currently, tumor DNA is sequenced, and genomics reports are given to physicians to help select targeted therapies for patients. While this genome-centric approach to precision oncology has extended the lives of subsets of patients, many patients do not respond to the selected therapy, and many whose tumors initially respond have a high chance of recurrence with resistant disease. New approaches are required to capture complex clinical phenotypes and better match patients to efficacious therapies.

Most molecularly targeted therapies (e.g., kinase inhibitors, immune checkpoint inhibitors) do not directly target the cancer genome but rather target proteins in cancer cells or the tumor microenvironment. Neither DNA nor RNA profiles are reliable indicators of protein expression or activity levels. Thus, directly quantifying the expression of target proteins and their networks throughout all phases of precision oncology, from drug development through to patient selection, is critically important.

This webinar will discuss the added value of proteogenomics to the current genome-driven approach to precision oncology. The speaker will summarize the growing incorporation of targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry into: preclinical research; clinical trials and; clinical laboratories to support target discovery, pharmacodynamic and mechanism of action studies (e.g., PMID: 30385821, 34359745), correlative studies (e.g., PMID: 36259971) and the quantification of diagnostic proteins (e.g., PMID: 36388059). The establishment of proteomics represents an important component towards implementation of broader precision medicine efforts in oncology and beyond. (See also: PMID: 30487530 and PMID: 33798439.)

Register for this webinar to learn about the advantage of using proteomics to build next-gen diagnostic solutions for precision oncology.

Join Dr. Amanda Paulovich, MD, PhD, Professor and Aven Foundation Endowed Chair, Director, CLIA Targeted Proteomic Laboratory, Clinical Research Division, Fred Hutchinson Cancer Center, for the live webinar on Thursday, April 20, 2023, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Precision Oncology Approaches: Using Proteomics to Build Next-Gen Diagnostic Solutions.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email: